WPD Pharmaceuticals Inc. (WPDPF) Stock Analysis
DELISTED 2026
What happened to WPD Pharmaceuticals Inc. (WPDPF) stock?
WPD Pharmaceuticals Inc. (WPDPF) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
WPD Pharmaceuticals Inc. (WPDPF) trades at $0.00003. WPD Pharmaceuticals Inc. is a biotechnology company focused on the research and development of medicinal products for oncology and infectious diseases. Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for WPDPF: WPDPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WPDPF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
WPDPF: 2/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →WPD Pharmaceuticals Inc. (WPDPF) Healthcare & Pipeline Overview
WPD Pharmaceuticals Inc. is a Canadian biotechnology firm specializing in the development of novel therapies for oncology and infectious diseases. With a pipeline spanning pre-clinical to Phase I/II clinical trials, the company focuses on addressing unmet needs in areas such as glioblastoma, pancreatic cancer, and acute myeloid leukemia, operating in a competitive and highly regulated environment.
What Is the Investment Thesis for WPDPF?
WPD Pharmaceuticals Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value is primarily driven by the potential success of its drug pipeline, particularly Berubicin and Annamycin, which are in Phase 1 and Phase I/II clinical trials, respectively. Positive clinical trial results could serve as significant catalysts, driving up the company's valuation. However, the company's negative P/E ratio of -99.29 reflects its current lack of profitability and reliance on future drug approvals. The OTC market listing introduces additional liquidity and regulatory risks. Successful navigation of clinical trials and regulatory hurdles is crucial for realizing the company's potential value. Investors should carefully consider the inherent risks and potential rewards associated with biotechnology investments, particularly for companies in early stages of development.
Based on FMP financials and quantitative analysis
WPDPF Key Highlights
WPD Pharmaceuticals Inc. is focused on oncology and infectious disease drug development.
- The company has a diverse pipeline of drug candidates in various stages of pre-clinical and clinical trials.
- Berubicin is in Phase 1 clinical trials for the treatment of glioblastoma.
- Annamycin is in Phase I/II clinical trials for the treatment of acute myeloid leukemia (AML) and metastasis to lungs.
- The company's P/E ratio is -99.29, reflecting its current lack of profitability.
Who Are WPDPF's Competitors?
WPDPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WPDPF's Key Strengths?
Diverse pipeline of drug candidates targeting oncology and infectious diseases.
- Drug candidates in various stages of pre-clinical and clinical development.
- Focus on addressing unmet medical needs in critical therapeutic areas.
- Experienced management team with expertise in drug development.
What Are WPDPF's Weaknesses?
Limited financial resources and reliance on external funding.
- High dependence on the success of key drug candidates.
- Lack of commercialized products and revenue generation.
- Small company size with limited infrastructure.
What Could Drive WPDPF Stock Higher?
Results from Phase 1 clinical trials for Berubicin in glioblastoma (2026).
- Results from Phase I/II clinical trials for Annamycin in AML and metastasis to lungs (2026-2027).
- Initiation of new clinical trials for other drug candidates in the pipeline (2026-2027).
- Potential for strategic partnerships and licensing agreements with larger pharmaceutical companies.
- Continued progress in pre-clinical development of drug candidates.
What Are the Key Risks for WPDPF?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure of drug candidates in clinical trials.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies with greater resources.
- Limited financial resources and reliance on external funding.
- Risks associated with operating in the OTC market, including limited liquidity and regulatory oversight.
What Are the Growth Opportunities for WPDPF?
- Advancement of Berubicin through Clinical Trials: Berubicin, currently in Phase 1 clinical trials for glioblastoma, represents a significant growth opportunity for WPD Pharmaceuticals. Positive results from these trials could lead to further clinical development and eventual commercialization, addressing a critical unmet need in brain cancer treatment. Timeline: Ongoing, with Phase 1 trial results expected in the near term.
- Progression of Annamycin in AML Treatment: Annamycin, in Phase I/II clinical trials for acute myeloid leukemia (AML) and metastasis to lungs, presents another key growth driver. Success in these trials could position Annamycin as a valuable treatment option for AML, a hematologic malignancy with a significant patient population. The market for AML treatments is substantial, driven by the need for more effective therapies. Timeline: Ongoing, with Phase I/II trial results anticipated over the next few years.
- Development of WPD1066 for CNS and Pancreatic Cancers: WPD1066, currently in Phase 1 clinical trials for central nervous system tumors, pancreatic cancer, and ocular tumors, offers a broad therapeutic potential. Positive outcomes in these trials could lead to the development of treatments for multiple cancer types, expanding the company's market reach and revenue streams. The combined market for these cancers is substantial. Timeline: Ongoing, with Phase 1 trial results expected in the coming years.
- Expansion of Pre-clinical Pipeline: WPD Pharmaceuticals' pre-clinical pipeline, including WPD101, WPD102, WP1732, WP1220, and WPD103, represents a longer-term growth opportunity. Successful pre-clinical development could lead to new drug candidates entering clinical trials, further diversifying the company's pipeline and reducing its reliance on existing programs. This expansion could attract additional investment and partnerships. Timeline: Long-term, with pre-clinical programs requiring several years to advance to clinical stages.
- Strategic Partnerships and Licensing Agreements: WPD Pharmaceuticals can pursue growth through strategic partnerships and licensing agreements with larger pharmaceutical companies. These collaborations can provide funding, expertise, and resources to accelerate the development and commercialization of its drug candidates. Successful partnerships could generate upfront payments, milestone payments, and royalties, significantly boosting the company's financial position. Timeline: Ongoing, with potential partnerships and agreements possible at any time.
What Are WPDPF's Competitive Advantages?
- Intellectual property protection (patents on drug candidates)
- Proprietary drug development platform
- Specialized expertise in oncology and infectious diseases
- Established relationships with research institutions
What Does WPDPF Do?
WPD Pharmaceuticals Inc., headquartered in Vancouver, Canada, is a biotechnology company dedicated to the research and development of innovative medicinal products. Founded with the aim of addressing critical unmet needs in oncology and infectious diseases, the company has built a pipeline of drug candidates targeting a range of conditions. Its portfolio includes WPD101, a pre-clinical stage treatment for brain cancers, including glioblastoma; WPD102, a pre-clinical stage treatment for Uval Melanoma; Berubicin, currently in Phase 1 clinical trials for glioblastoma; and WP1066, in Phase 1 clinical trials for central nervous system tumors, pancreatic cancer, and ocular tumors. Further expanding its therapeutic scope, WPD Pharmaceuticals is also developing WP1732 for pancreatic cancer, WP1220 for cutaneous T-cell lymphoma, and WPD103 for glioblastoma multiforme, all in pre-clinical stages. Annamycin, a treatment for acute myeloid leukemia (AML) and metastasis to lungs, is in Phase I/II clinical trials. The company's strategy involves preclinical research, clinical trials, and strategic partnerships to advance its drug candidates through the regulatory approval process and ultimately to market. With a focus on innovative therapies and a commitment to addressing significant medical challenges, WPD Pharmaceuticals aims to improve patient outcomes and contribute to advancements in the treatment of cancer and infectious diseases.
What Products and Services Does WPDPF Offer?
- Researches and develops medicinal products for oncology.
- Develops treatments for infectious diseases.
- Conducts pre-clinical trials for drug candidates.
- Conducts Phase 1 and Phase I/II clinical trials.
- Focuses on treatments for brain cancers, including glioblastoma.
- Develops therapies for acute myeloid leukemia (AML) and metastasis to lungs.
- Aims to address unmet medical needs in cancer and infectious diseases.
How Does WPDPF Make Money?
- Develops drug candidates through internal research and development.
- Conducts pre-clinical and clinical trials to evaluate drug efficacy and safety.
- Seeks regulatory approval from agencies like the FDA and EMA.
- Potentially commercializes approved drugs directly or through partnerships.
What Industry Does WPDPF Operate In?
WPD Pharmaceuticals Inc. operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital expenditure. The oncology and infectious disease segments are particularly active, driven by the growing global burden of these diseases. Key trends include the rise of personalized medicine, advancements in immunotherapy, and the increasing focus on targeted therapies. WPD Pharmaceuticals competes with both large pharmaceutical companies and smaller biotech firms, including CRXM, CRYO, GDBYF, GLSHQ, and GNBT, all vying for market share and investment in innovative drug development.
Who Are WPDPF's Key Customers?
- Pharmaceutical companies (potential partners or licensees)
- Hospitals and cancer centers (potential end-users of approved drugs)
- Patients suffering from cancer and infectious diseases
- Research institutions (collaborators in drug development)
Financial Health
WPD Pharmaceuticals Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for WPD Pharmaceuticals Inc. stands at 15.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.1%, showing how much profit it generates from its asset base. A current ratio of 0.20 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
WPD Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Mariusz Olejniczak. WPDPF has traded publicly since 2020.
WPDPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Diverse pipeline of drug candidates targeting oncology and infectious diseases.
- Drug candidates in various stages of pre-clinical and clinical development.
- Focus on addressing unmet medical needs in critical therapeutic areas.
- Experienced management team with expertise in drug development.
Bear Case
- Limited financial resources and reliance on external funding.
- High dependence on the success of key drug candidates.
- Lack of commercialized products and revenue generation.
- Small company size with limited infrastructure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
WPDPF Latest News
No recent news available for WPDPF.
Leadership: Mariusz Olejniczak
CEO
Mariusz Olejniczak serves as the CEO of WPD Pharmaceuticals Inc. His background includes experience in managing and overseeing pharmaceutical research and development activities. He is responsible for guiding the company's strategic direction, managing its operations, and ensuring the advancement of its drug pipeline. His leadership is crucial for navigating the complex regulatory landscape and securing funding for the company's research programs. He oversees a team of 16 employees.
Track Record: Under Mariusz Olejniczak's leadership, WPD Pharmaceuticals has focused on advancing its drug candidates through pre-clinical and clinical trials. Key milestones include the progression of Berubicin to Phase 1 clinical trials and Annamycin to Phase I/II clinical trials. He has also been instrumental in securing partnerships and funding to support the company's research and development efforts. His tenure has been marked by a focus on building a diverse drug pipeline and addressing unmet medical needs in oncology and infectious diseases.
WPDPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that WPD Pharmaceuticals Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, potentially increasing investment risk.
- OTC Tier: OTC Other
- Limited liquidity and potential price volatility.
- Lack of regulatory oversight and disclosure requirements.
- Higher risk of fraud and manipulation compared to major exchanges.
- Potential for delisting or trading suspension.
- Limited access to company information and financial statements.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Presence of a professional website and investor relations materials.
- Active engagement with shareholders and the investment community.
- Independent audit of financial statements (if available).
- Clear articulation of the company's business strategy and goals.
- Experienced management team with relevant industry expertise.
WPD Pharmaceuticals Inc. Healthcare Stock: Key Questions Answered
What happened to WPD Pharmaceuticals Inc. (WPDPF) stock?
WPD Pharmaceuticals Inc. (WPDPF) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
Can I still buy WPDPF shares?
No. WPDPF stopped trading on public markets in April 2026, so the shares are not available through a broker. Anything you see quoted for WPDPF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before WPDPF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to WPD Pharmaceuticals Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does WPD Pharmaceuticals Inc. do?
WPD Pharmaceuticals Inc. is a biotechnology company focused on the research and development of medicinal products in the fields of oncology and infectious diseases. The company develops novel therapies targeting conditions like glioblastoma, pancreatic cancer, and acute myeloid leukemia (AML).
What do analysts say about WPDPF stock?
As of 2026-03-16, there is no readily available analyst coverage or consensus for WPDPF stock due to its OTC listing and small market capitalization. Key valuation metrics such as the negative P/E ratio of -99.29 reflect the company's current lack of profitability. Growth considerations hinge on the successful advancement of its drug pipeline through clinical trials and regulatory approval.
What are the main risks for WPDPF?
The main risks for WPD Pharmaceuticals Inc. include the potential failure of drug candidates in clinical trials, regulatory hurdles and delays in drug approval, and competition from larger pharmaceutical companies with greater resources. Additionally, the company faces financial risks due to its limited resources and reliance on external funding.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited and subject to inaccuracies.